Company intelligence / Profile preview
Joincare Pharmaceutical
- Ownership
- Private
- Employees
- ~14000
- Development stage
- Other
Overview
Joincare has built a diversified pipeline with over twenty innovative drug programs; ten have reached Phase 2 or later stages, targeting respiratory, autoimmune, pain, metabolic, and CNS diseases, with commercial generics and innovative therapies (notably, mapacitasvir for influenza and BA2101 for severe asthma/COPD).
- Therapeutic areas
- ImmunologyPulmonologyInfectious DiseasesNeurologyWomen's HealthMetabolic DisordersDermatologyPsychiatry
- Modalities
- Small moleculeMonoclonal antibodyAntibodyInhaled preparationSustained-release microspheresNano lipid microemulsionSmall nucleic acid
- Industry
- Biotech
Drug pipeline
13 assets12 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Joincare Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Joincare Pharmaceutical.